Apollomics
APLM
11 hedge funds and large institutions have $323K invested in Apollomics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
7.12% less ownership
Funds ownership: 9.21% → 2.09% (-7.1%)
85% less capital invested
Capital invested by funds: $2.11M → $323K (-$1.78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$144K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$68.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$21.1K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.9K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$3.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.81M |
| 2 |
GKFF
George Kaiser Family Foundation
Tulsa,
Oklahoma
|
-$141K |
| 3 |
Renaissance Technologies
New York
|
-$12K |
APLM Hedge Fund Activity: Q3 2024 in Review
11 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Apollomics (APLM) for Q3 2024, worth a combined $323K — down 85% from $2.11M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new APLM positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Exchange Traded Concepts, adding an estimated $144K. The largest seller was OrbiMed, exiting entirely with an estimated $1.81M sold.
- 11 institutional investors held Apollomics (APLM) as of Q3 2024, up from 10 in Q2 2024.
- Funds reported $323K of Apollomics stock for Q3 2024, down 85% quarter-over-quarter.
- 4 funds opened new Apollomics positions in Q3 2024 and 3 closed out, a net change of +1 holder.
- The largest Apollomics buyer in Q3 2024 was Exchange Traded Concepts, an estimated $144K added.
- The largest Apollomics seller in Q3 2024 was OrbiMed, an estimated $1.81M sold.
Based on aggregated 13F filings for Q3 2024.